Document Detail

Reduction in First and Recurrent Cardiovascular Events with Ticagrelor Compared with Clopidogrel in the PLATO Study.
MedLine Citation:
PMID:  23277305     Owner:  NLM     Status:  Publisher    
BACKGROUND: We sought to evaluate the effect of potent platelet inhibition following acute coronary syndrome on total (i.e. first and recurrent) occurrences of any of the primary outcome events (e.g. cardiovascular death, myocardial infarction, and stroke) as well as on other ischemic events, such as urgent revascularization, (severe) recurrent ischemia (SRI/RI), transient ischemic attacks (TIA) and arterial thrombotic events (ATE). METHODS AND RESULTS: In the PLATelet inhibition and patient Outcomes (PLATO) study, 18,624 patients presenting with acute coronary syndromes randomly received ticagrelor (N=9333) or clopidogrel (N=9291). Cox proportional hazard models were used to calculate time to first event and hazard ratios. Total events were compared using a Poisson regression model and time to second event or death was calculated with the Wei Lin Weissfeld method. Patients randomized to ticagrelor had 1057 total primary endpoint events vs. 1225 for patients on clopidogrel (rate ratio=0.86, 95% CI 0.79-0.93, p=0.003). The number of additional events was numerically lower for ticagrelor (189 vs. 205, p=0.40), resulting in a hazard for time to second event/death of 0.80 (95% CI 0.70-0.90, p<0.001) and a number needed to treat of 54. For CVD/MI/Stroke/SRI/RI/TIA/ATE, total events were fewer with ticagrelor (2030 vs. 2290, rate ratio 0.88, 95% CI 0.82-0.95, p<0.001), with fewer recurrent events with ticagrelor (740 vs. 834, p=0.01) and a highly significant concurrent reduction in hazard for time to second event or death of 0.83 (95% CI 0.75-0.91, p<0.001). Recurrent PLATO major or TIMI major non-CABG bleeding events were infrequent and not different between the two therapies (p=0.96 and 0.38, respectively). CONCLUSIONS: In PLATO, treatment with ticagrelor compared with clopidogrel resulted in a reduction in total events, including first and subsequent recurrent cardiovascular events, when compared to clopidogrel. These types of analyses demonstrate an even greater absolute benefit of ticagrelor over clopidogrel than previously reported. CLINICAL TRIAL REGISTRATION INFORMATION: Identifier: NCT00391872.
Payal Kohli; Lars Wallentin; Eric Reyes; Jay Horrow; Steen Husted; Dominick J Angiolillo; Diego Ardissino; Gerald Maurer; Joao Morais; José C Nicolau; Ali Oto; Robert F Storey; Stefan K James; Christopher P Cannon
Related Documents :
21371455 - A novel anti-fibrotic agent, baicalein, for the treatment of myocardial fibrosis in spo...
6738045 - Serum creatine kinase and alkaline phosphatase in experimental small bowel infarction.
21343655 - The follow-up evaluation of electrocardiogram and arrhythmias in children with fulminan...
21212995 - Ischaemic stroke after acute intracranial haemorrhage in patients with moyamoya disease...
21063875 - Prognostic importance of comorbidities in heart failure with preserved left ventricular...
21940265 - Early and long-term prognosis of patients with coronary artery disease treated with per...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-31
Journal Detail:
Title:  Circulation     Volume:  -     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2013-1-1     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
1 BWH and Harvard Medical School, Boston, MA; Univ of California San Francisco, San Francisco, CA;
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Twelve-month follow-up of cognitive behavioral therapy for children with functional abdominal pain.
Next Document:  A History of Stroke/Transient Ischemic Attack Indicates High Risks of Cardiovascular Event and Hemor...